Skip to main content
. 2023 Jun 20;67(2):3667. doi: 10.4081/ejh.2023.3667

Figure 5.

Figure 5.

FBXO18-AS promoted cancer cell proliferation and invasion via TGF-β1/Smad signaling. a) MTS assays indicated that FBXO18-AS overexpression impacted the survival of SGC7901 cells, while this change was reversed after LY2109761 treatment (oneway ANOVA; p<0.01). b) Western blotting illustrated that FBXO18-AS overexpression affected vimentin and E-cadherin expression in SGC7901 cells; however, this change was reversed after LY2109761 treatment. c) EdU assays revealed that FBXO18-AS overexpression impacted SGC7901 cell proliferation, while this change was reversed after LY2109761 treatment; scale bars: 100 μm (p<0.001; Student’s t-test). d,e) Transwell (d) and migration assays (e) showed that FBXO18-AS overexpression affected SGC7901 cell invasion and migration, whereas this variation was reversed after LY2109761 treatment; scale bars: 50 μm (p<0.001; Student’s t-assay). The overall data are presented as the mean ± SD (three independent tests); ***p<0.001; **p<0.01; *p<0.05.